Your browser doesn't support javascript.
loading
Heart Failure with Mildly Reduced Ejection Fraction-A Phenotype Waiting to Be Explored.
Nair, Anugrah; Tuan, Lukah Q; Jones-Lewis, Natasha; Raja, Deep Chandh; Shroff, Jenish; Pathak, Rajeev Kumar.
Afiliação
  • Nair A; Department of Cardiac Electrophysiology, Canberra Heart Rhythm Centre, Canberra, ACT 2605, Australia.
  • Tuan LQ; ANU College of Health and Medicine, Australian National University, Acton Campus, Canberra, ACT 0200, Australia.
  • Jones-Lewis N; Department of Cardiac Electrophysiology, Canberra Heart Rhythm Centre, Canberra, ACT 2605, Australia.
  • Raja DC; ANU College of Health and Medicine, Australian National University, Acton Campus, Canberra, ACT 0200, Australia.
  • Shroff J; Department of Cardiac Electrophysiology, Canberra Heart Rhythm Centre, Canberra, ACT 2605, Australia.
  • Pathak RK; ANU College of Health and Medicine, Australian National University, Acton Campus, Canberra, ACT 0200, Australia.
J Cardiovasc Dev Dis ; 11(5)2024 May 09.
Article em En | MEDLINE | ID: mdl-38786970
ABSTRACT
Heart failure (HF) presents a significant global health challenge recognised by frequent hospitalisation and high mortality rates. The assessment of left ventricular (LV) ejection fraction (EF) plays a crucial role in diagnosing and predicting outcomes in HF, leading to its classification into preserved (HFpEF), reduced (HFrEF), and mildly reduced (HFmrEF) EF. HFmrEF shares features of both HFrEF and HFpEF but also exhibits distinct characteristics. Despite advancements, managing HFmrEF remains challenging due to its diverse presentation. Large-scale studies are needed to identify the predictors of clinical outcomes and treatment responses. Utilising biomarkers for phenotyping holds the potential for discovering new treatment targets. Given the uncertainty surrounding optimal management, individualised approaches are imperative for HFmrEF patients. This chapter examines HFmrEF, discusses the rationale for its re-classification, and elucidates HFmrEF's key attributes. Furthermore, it provides a comprehensive review of current treatment strategies for HFmrEF patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Cardiovasc Dev Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Cardiovasc Dev Dis Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália